DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology & Market Forecast–2030”.
Some facts of the report:
- Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.
- DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017
- Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.
- Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.
Key Benefits of the Report:
- Acute Respiratory Distress Syndrome Market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- Acute Respiratory Distress Syndrome market report provides insights on the current and emerging therapies.
- Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
- Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
“The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”
The launch of the emerging therapies is expected to significantly impact Postherpetic Neuralgia treatment scenario in the upcoming years:-
Drugs covered:
- Traumakine
- Bio-11006
- Ulinastatin
- MultiStem
- Solnatide (AP301)
- APN01 (GSK2586881)
- GSK2862277
- IC14
- Remodulin (Treprostinil Inhalation Solution)
The key players in Postherpetic Neuralgia market are:
- Faron Pharmaceuticals
- BioMarck Pharmaceuticals
- Techpool Bio-Pharma
- Athersys
- APEPTICO Forschung und Entwicklung GmbH
- Apeiron Biologics/GlaxoSmithKline
- GlaxoSmithKline
- Implicit Bioscience
- United Therapeutics
Table of Contents:
1. Key Insights
2. Executive Summary
3. Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of ARDS in 2017
3.2. Total Market Share (%) Distribution of ARDS in 2030
4. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
4.1. Introduction
4.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
4.1.2. Development of Berlin Definition of ARDS
4.1.3. Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress
syndrome (ARDS)
4.2. Causes and Risk Factors
4.2.1. Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
4.3. Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
4.3.1. Inflammatory Processes in ARDS
4.3.2. The initial event of injury
4.3.3. Endothelial Damage
4.3.4. Specific Mediators of Inflammation and Lung Damage in ARDS
4.3.5. Altered Pulmonary Physiology in ARDS
4.3.6. Genetics
4.4. Stages of Acute Respiratory Distress Syndrome (ARDS)
4.5. Ventilator-Induced Lung Injury (VILI)
4.6. Major Determinants of VILI
4.6.1. Ventilator determinants of VILI
4.6.2. Patient determinants of VILI
4.7. Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
4.7.1. Imaging techniques in ARDS
4.7.2. Imaging findings in ARDS
4.7.3. Differential Diagnosis
5. Case Reports
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology
7. 7MM Epidemiology Analysis
7.1. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
7.2. Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
8. United States Epidemiology
8.1. Assumptions and Rationale
8.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
8.3. Severity-specific Incident Population of ARDS in the United States
8.4. Incident Population of ARDS by Risk Factors in the United States
9. EU5 Epidemiology
9.1. Germany Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
9.1.3. Severity-specific Incidence of ARDS in Germany
9.1.4. Incident Population of ARDS by Risk Factors in Germany
9.2. France Epidemiology
9.2.1. Assumptions and Rationale
9.2.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in France
9.2.3. Severity-specific Incidence of ARDS in France
9.2.4. Incident Population of ARDS by Risk Factors in France
9.3. Italy Epidemiology
9.3.1. Assumptions and Rationale
9.3.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
9.3.3. Severity-specific Incidence of ARDS in Italy
9.3.4. Incident Population of ARDS by Risk Factors in Italy
9.4. Spain Epidemiology
9.4.1. Assumptions and Rationale
9.4.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
9.4.3. Severity-specific Incidence of ARDS in Spain
9.4.4. Incident Population of ARDS by Risk Factors in Spain
9.5. United Kingdom Epidemiology
9.5.1. Assumptions and Rationale
9.5.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
9.5.3. Severity-specific Incidence of ARDS in the United Kingdom
9.5.4. Incident Population of ARDS by Risk Factors in the United Kingdom
10. Japan Epidemiology
10.1.Assumptions and Rationale
10.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Japan
10.3. Severity-specific Incidence of ARDS in Japan
10.4. Incident Population of ARDS by Risk Factors in Japan
11. Treatment Algorithm, Current Treatment, and Medical Practices
11.1. Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)
12. Proposed Guidelines for ARDS
12.1.An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical
Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute
Respiratory Distress Syndrome
12.2. The Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese
Society of Intensive Care Medicine for the management of ARDS in Japan
13. Unmet Needs
14. Off-Label Therapies for ARDS
14.1.Neuromuscular Blocking Agents (NMBAs)
14.1.1. Product Description
14.1.2. Mechanism of Action
14.1.3. Advantages and Disadvantages
14.1.4. Clinical Development
14.2. Inhaled Vasodilators
14.2.1. Product Description
14.2.2. Inhaled Pulmonary Vasodilators
14.2.3. Advantages and Disadvantages
14.2.4. Clinical Development
14.3. Corticosteroids
14.3.1. Product Description
14.3.2. Mechanism of Action
14.3.3. Advantages and Disadvantages
14.3.4. Clinical Development
15. Emerging Therapies
15.1.Key Cross Competition
15.2. Traumakine: Faron Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.2.4. Clinical Trials Information
15.2.5. Safety and Efficacy
15.2.6. Product Profile
15.3.Bio-11006: BioMarck Pharmaceuticals
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Clinical Trials Information
15.3.5. Product Profile
15.4.Ulinastatin: Techpool Bio-Pharma
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.4.4. Clinical Trials Information
15.4.5. Product Profile
15.5.MultiStem: Athersys
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development
15.5.4. Clinical Trials Information
15.5.5. Safety and Efficacy
15.5.6. Product Profile
15.6. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
15.6.1. Product Description
15.6.2. Other Developmental Activities
15.6.3. Clinical Development
15.6.4. Clinical Trials Information
15.6.5. Safety and Efficacy
15.6.6. Product Profile
List to be continued in the report……
16. Discontinued Products
16.1.APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
16.1.1. Product Description
16.1.2. Other Developmental Activities
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.1.5. Product Profile
16.2.GSK2862277: GlaxoSmithKline
16.2.1. Product Description
16.2.2. Other Developmental Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.2.5. Product Profile
16.3. IC14: Implicit Bioscience
16.3.1. Product Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.3.4. Product Profile
16.4.Remodulin (Treprostinil Inhalation Solution): United Therapeutics
16.4.1. Product Description
16.4.2. Other Developmental Activities
16.4.3. Clinical Development
16.4.4. Clinical Trials Information
16.4.5. Product Profile
17. Acute Respiratory Distress Syndrome (ARDS): 7MM Analysis
17.1. Key Findings
17.2.Market Forecast Assumptions
17.3.Market Size of ARDS in the 7MM countries
17.4.Market Size of ARDS by therapies in the 7MM
18. United States: Market Outlook
19. United States Market Size
19.1.1. Total Market size of ARDS
19.1.2. Market Size of ARDS by Therapies in the US
20. EU-5 Countries: Market Outlook
20.1.Germany Market Size
20.1.1. Total Market Size of ARDS
20.1.2. Market Size of ARDS by Therapies in Germany
20.2. France Market Size
20.2.1. Total Market Size of ARDS
20.2.2. Market Size of ARDS by Therapies in France
20.3. Italy Market Size
20.3.1. Total Market Size of ARDS
20.3.2. Market Size of ARDS by Therapies in Italy
20.4. Spain Market Size
20.4.1. Total Market Size of ARDS
20.4.2. Market Size of ARDS by Therapies in Spain
20.5.United Kingdom Market Size
20.5.1. Total Market Size of ARDS
20.5.2. Market Size of ARDS by Therapies in the UK
21. Japan Market Outlook
21.1.Japan Market Size
21.1.1. Total Market Size of ARDS
21.1.2. Market Size of ARDS by Therapies in Japan
22. Market Drivers
23. Market Barriers
24. SWOT Analysis
25. KOL Views
26. Appendix
26.1.Report Methodology
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/